Background Patients with decompensated cirrhosis have high morbidity and are commonly hospitalized with acute kidney injury. Aims We examined serum levels of Siglec-7, a transmembrane receptor that regulates immune activity, as a biomarker for mortality in patients with cirrhosis and acute kidney injury. Methods Serum Siglec-7 was measured in hospitalized patients with cirrhosis and acute kidney injury, as well as in reference groups with acute liver injury/acute kidney injury, cirrhosis without acute kidney injury, and sepsis without liver disease. Clinical characteristics and subsequent outcomes were examined using univariate and multivariable analyses according to initial Siglec-7 levels.
Introduction
Decompensated cirrhosis is a common and morbid condition [1, 2] . Despite recent improvements in therapy, only modest reductions in cirrhosis-related mortality have been observed [3] . Many patients with cirrhosis require hospitalization for acute decompensation, such as from acute kidney injury (AKI) [1, 4, 5] . It is estimated that up to 50 % of those with decompensated cirrhosis will suffer from AKI, including 20 % diagnosed with hepatorenal syndrome (HRS) [6, 7] . Commonly used risk prediction tools, such as the Model for End-Stage Liver Disease (MELD) score, may not fully capture the added mortality risk that stems from complications like AKI [8] [9] [10] . Increasingly, we have recognized the role of immune dysregulation and local hepatic and endothelial inflammation in the pathogenesis of complications of advanced liver disease. A serum biomarker that helps quantify such inflammation could identify those at high risk for poor outcomes and refine our ability to estimate survival in this population.
Sialic-acid-binding immunoglobulin-like lectin-7, or Siglec-7, is a member of a family of transmembrane receptor proteins that may hold potential as an important biomarker in decompensated liver disease. Siglecs are expressed on cells of the innate immune system and regulate inflammation [11, 12] . Siglec-7 is found predominantly on natural killer cells, as well as monocytes, some T cells, and cells in the intestine and liver [13] [14] [15] [16] [17] . Siglec-7 is a 51-kDa inhibitory receptor that down-regulates innate immunity when activated [18] [19] [20] . This mechanism is manipulated by several pathogens and tumors in order to subvert host immune response, including HIV and hepatitis C infections [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] . In addition, a recent publication showed that in chronic hepatitis C infection, known markers of liver inflammation and advanced fibrosis correlated with increasing soluble serum Siglec-7 levels, but no study has yet investigated the association of Siglec-7 and concrete clinical outcomes in liver disease, such as survival [14] .
Given this recent publication showing relationship between Siglec-7 and biochemical liver injury, we sought to evaluate serum Siglec-7 as a biomarker for mortality in decompensated liver disease with an exploratory study design. We analyzed serum Siglec-7 in a hospitalized cohort with cirrhosis and AKI in order to determine the relationship between Siglec-7 and survival. Sub-analysis was performed to determine whether the etiology of AKI (see ''Definitions'') impacted Siglec-7 levels. We hypothesized that increased serum Siglec-7 levels would be associated with higher mortality. We also hypothesized that Siglec-7 would be preferentially elevated in HRS compared to other types of AKI, as hepatic vascular inflammation and vasodilation is thought to play a role in the pathogenesis of HRS [31] [32] [33] .
Methods Study Population and Setting
Between January 2013 and April 2014, adults (age [18 years) who were hospitalized at Massachusetts General Hospital and meeting entry criteria were enrolled and followed prospectively for 90 days from hospital admission. Subjects were included if they had decompensated cirrhosis and AKI. Additional reference groups were also included to compare Siglec-7 levels in those with (a) acute liver injury and AKI, (b) decompensated cirrhosis without AKI, and (c) sepsis without liver disease. Potential subjects were excluded if they were pregnant or nursing.
Definitions of Diagnoses
Diagnoses of decompensated cirrhosis, acute liver injury, and etiology of cirrhosis were based on clinical evaluation by the treating hepatologist. A member of the research team performed an in-depth review of medical record to ensure accuracy. Etiology of cirrhosis was listed as multifactorial if there were C2 causes felt to be contributing to cirrhosis. Subjects were classified as having decompensated cirrhosis if they were diagnosed with cirrhosis prior to or during the index study admission. The Acute Kidney Injury Network (AKIN) criteria were used to diagnose AKI [34] . Acute kidney injury was classified into one of four subgroups by etiology: (1) prerenal kidney injury (resolution of AKI within 48 h after volume resuscitation), (2) acute tubular necrosis (clinical history consistent with ischemic or nephrotoxic AKI and failure to respond to volume administration), (3) HRS (exclusion of other potential causes of AKI based on the 2007 Ascites Club Criteria) [35] , or (4) other AKI (evidence of another process on serology or renal biopsy, such as glomerulonephritis). Sepsis was defined per the Surviving Sepsis Campaign [36] .
Data Collection and Outcomes
All data except for Siglec-7 measurements were registered as part of routine clinical care and taken from review of the medical record. Model for End-Stage Liver Disease (MELD) score was calculated at the time of admission [8, 37] . Participants provided serum, plasma, and urine samples on enrollment and day 5 and 30 after enrollment (as available) for longitudinal analysis of Siglec-7 and future evaluation of novel biomarkers of kidney and liver injury. Members of the study team did not participate or intervene in the clinical care of the subjects. The primary outcome for this study was all-cause mortality at 90 days. The primary outcome was modeled only for those with cirrhosis and AKI.
Measurement of Serum Siglec-7
Serum Siglec-7 levels were measured using a commercially available quantitative ELISA assay (Catalog number DY1138, R&D Systems, MN). This assay is specific for Siglec-7 and is not reported to cross-react to Siglecs 2, 3, 5, 9, and 10. The coefficient of variation for this assay is \10 %. Given this assay is not yet FDA-approved for clinical use, results of Siglec-7 testing were not made available to the clinical care team.
Statistical Analysis
Subjects were divided into two equally sized groups (''high'' vs. ''low'' serum Siglec-7 levels) by dividing at the median value for the primary analysis group (4241 pg/mL). Differences in the primary outcome of death by 90 days by high/low Siglec-7 level were visualized using a KaplanMeier curve and compared using a log-rank test. A prespecified Cox proportional hazard model was selected for analysis of mortality by high/low Siglec-7 level after adjusting for age and MELD score. Five sensitivity analyses of the primary outcome were performed: (1) including all 118 subjects with liver disease (irrespective of AKI status), (2) using the optimally derived cut-point for Siglec-7 by receiver operating characteristic (ROC) curve analysis [38] , (3) excluding subjects with either prior liver transplant, HIV positive status, or hepatocellular carcinoma, (4) using a composite outcome of liver transplantation or death by 90 days, and (5) stratified analysis by hepatitis C infection status. The assumption of proportional hazards was accessed for all models using Martingale residuals. No evidence of non-proportional hazards was detected. Results of Cox proportional hazard models are summarized with hazard ratios and Wald asymptotic 95 % confidence intervals. All model assumptions were checked and given a normal distribution of deviance residuals, parametric testing was used for all univariate and multivariable analysis, and continuous variables were presented as means and 95 % confidence intervals. Descriptive tables and figures were generated using Student's t tests, paired t tests, Chi-square tests (or Fisher's exact test when cells contained \5 observations), Pearson correlation, and analysis of variance (ANOVA), as appropriate. For all subjects with liver disease where the calculation of a MELD score was appropriate, the incremental improvement of adding Siglec-7 to models containing (1) MELD score, MELD-Na score [39] , and (2) MELD score, age, and presence of cirrhosis/acute liver injury/AKI was measured by c statistic, category-free net reclassification index (NRI) and integrated discrimination index (IDI) [40] . SAS version 9.4 (Gary, NC) and R version 3.2.2 were used for analysis [41] . Two-tailed p values \0.05 were considered statistically significant. Given the exploratory design of this study and lack of prior data of serum Siglec-7 in decompensated liver disease, no formal power calculation was performed.
Ethics Statement
This study was approved by the site's institutional review board and abides by the guidelines set forth by the Declaration of Helsinki. No donor organs were obtained from executed prisoners or other institutionalized persons at this liver transplant center. All participants (or their health care designee) provided written informed consent.
Results

General Demographics
Serum Siglec-7 levels were analyzed in 128 hospitalized subjects: 92 with cirrhosis and AKI (primary analysis group), 9 with acute liver injury and AKI, 17 with decompensated cirrhosis and no AKI, and 10 with sepsis and no liver disease. In the primary cohort of those with cirrhosis and AKI, average age was 57 [55, 60] years, 72 % were male, 90 % were of White race, and 88 % were of non-Hispanic ethnicity. Average length of inpatient stay Dig Dis Sci (2016) 61:3609-3620 3611 was 18 [15, 22] Table 2 for a comparison of clinical characteristics by disease group. In the primary analysis group, subjects with high Siglec-7 levels had significantly higher MELD scores (28 [25, 30] vs. 21 [19, 23] ; p \ 0.001) compared to those with low Siglec-7 levels. Pearson correlation between continuous serum Siglec-7 levels and several clinical variables was reported in Fig. 2 , including MELD score (and its components), AST, ALT, and AST to platelet ratio index (APRI). Only 6 subjects had a liver biopsy available, and thus correlation between Siglec-7 and fibrosis stage was not performed.
Among those with cirrhosis and AKI (n = 92), 33 (36 %) had prerenal AKI, 25 (27 %) had HRS, 26 (28 %) had acute tubular necrosis, and the remaining 8 (9 %) had other AKI. There was no difference in Siglec-7 levels by etiology of AKI (4707 [ [1.30, 4.27] ; p = 0.005). Among 63 subjects without hepatitis C infection, the unadjusted hazard ratio of death for high Siglec-7 was 2.32 [1.16, 4 .65]; p = 0.02. Among 29 subjects with hepatitis C infection, the unadjusted hazard ratio of death for high Siglec-7 was nonsignificant (1.52 [0.50, 4.64]; p = 0.47). Adjusted analysis was not performed for these subgroups due small sample sizes.
Added Usefulness of Siglec-7 to Predict Mortality
Among all subjects with liver disease (n = 118), MELD score on hospital admission predicted 90-day mortality with a c statistic of 0.64. As a continuous measure, serum Siglec-7 predicted 90-mortality with a c statistic of 0.66. Addition of serum Siglec-7 to MELD score improved the c statistic to 0.68, with a category-free NRI of 0.38 (p = 0.04), and an IDI of 0.043 (p = 0.03). Results were similar when serum Siglec-7 was added to MELD-Na score. In a multivariable model to predict 90-day mortality containing age, MELD score, and presence of cirrhosis/ acute liver injury/AKI, the c statistic was 0.76. Addition of serum Siglec-7 to this model improved the c statistic to 0.78, with a category-free NRI of 0.41 (p = 0.03) and an IDI of 0.052 (p = 0.02; see Table 3 ).
Siglec-7 Before and After Liver Transplant
Nine subjects had Siglec-7 levels measured 30 days after their initial sample (Fig. 4) . Five of those subjects underwent liver transplantation between the two measurements. Siglec-7 levels decreased significantly after liver transplantation by 3809 [1944, 5674] pg/mL (p = 0.005). There was no decrease in Siglec-7 levels among the four subjects who did not undergo liver transplantation (-97 [-1951 , 2144] pg/mL; p = 0.89).
Discussion
Currently, there are several tools at physicians' disposal to help predict mortality in those with advanced liver disease. These include clinical prediction models, like the MELD score, as well as markers of advanced fibrosis, such as liver biopsy, APRI, and ultrasound elastography [1, 42] .
However, these models and markers may be limited at capturing the relative increased mortality associated with acute decompensation of cirrhosis, especially in those who are hospitalized with AKI [9, 10] . Markers of immune function and regulation of inflammation, like Siglec-7, may provide insight into pathways that are affected by these clinical insults. In our cohort of subjects hospitalized with advanced liver disease, including decompensated cirrhosis, acute liver injury, and acute kidney injury, serum Siglec-7 was associated with increased mortality in adjusted and unadjusted analysis. Addition of Siglec-7 to clinical prognostic scores resulted in improvement in predictive ability for 90-day mortality, suggesting that this biomarker may provide added value to existing clinical prognostic tools.
An elegant recent publication by Varchetta et al. [14] highlighted the potential pathobiologic connection between Siglec-7, immune dysregulation, and severe liver disease. In a large cross-sectional study, these investigators demonstrated an increase in soluble serum Siglec-7 in a population with hepatitis C infection, and a correlation between Siglec-7 and levels of other clinical biomarkers of liver disease. This suggests that higher soluble Siglec-7 may denote a high inflammatory state in the liver and may be mechanistically important in this disease process. In Fig. 2 , we show similar correlation coefficients between Siglec-7 and these serologies as Varchetta et al. [14] did, highlighting the reproducibility of the Siglec-7 assay in a distinct population. We are able to build on these findings in our prospective study by extending that serum Siglec-7 levels were associated with increased mortality in an independent cohort. This helps confirm an important connection between liver inflammation, immune dysregulation, and clinical outcomes in cirrhosis. We showed these results in a more heterogeneous population of liver disease, expanding the application of Siglec-7 beyond those with only viral hepatitis. Several of our results support serum Siglec-7 may be a specific clinical marker in liver disease. First, Siglec-7 levels in the three subgroups with liver disease were higher than those hospitalized without liver disease. Second, Siglec-7 levels were similar between those with AKI and those without AKI, suggesting that levels were not affected by renal dysfunction. We originally hypothesized that Siglec-7 would differ across subtypes of AKI due to varying levels of inflammatory involvement depending on the type of AKI. Although this hypothesis was not confirmed, it is reassuring that Siglec-7 measurements correlated best with overall survival rather than a specific etiology of AKI. This may speak to the complicated pathophysiology of processes like hepatorenal syndrome, which is highlighted in the updated diagnostic criteria set forth by the International Ascites Club [43] . In our cohort, the presence of AKI itself predicted higher mortality. Even though MELD score captures a higher risk of death in these subjects (given that higher serum creatinine translates into more MELD points), serum Siglec-7 still added incremental value in predicting mortality when added to the MELD score (as well as to a multivariable model that included MELD score). In fact, the c statistic of serum Siglec-7 alone was similar to that of MELD score. It is biologically interesting that a single lab test-serum Siglec-7-had a similar predictive value to the reference standard of MELD score, which requires three clinical laboratory components for calculation. We observed only a weak statistical correlation between Siglec-7 and MELD score, suggesting that the biologic pathways these predictors measure may be independent. Regardless of its pathway, there may be tremendous value in a single, clinically available biomarker like serum Siglec-7 that has such strong predictive power for mortality. Fig. 3 Ninety-day probability of survival by high or low serum Siglec-7 level. Siglec-7 dichotomized at the median for all hospitalized subjects (4241 pg/mL) Additionally, we noted that serum Siglec-7 decreased dramatically following liver transplantation, suggesting its production is influenced by injured hepatocytes. There may be some additional effect from transplant immunosuppressive medications as well, though this is hard to quantify. Because our sample size for this cohort was small, additional study of this subgroup is needed to draw firm conclusions. Further study is also needed to determine the longitudinal effect of other supportive treatments in this population, as Siglec-7 levels decreased among those with repeated values who were alive at 90 days and did not change among those who had died by 90 days. It may be that trends of repeated measurements of Siglec-7 may hold prognostic value over time.
It is possible that Siglec-7 is not just a biomarker of disease activity, but a damage-associated molecule as well. Prior data suggest that natural killer cells, which express Siglec-7, are important in controlling liver fibrosis [44, 45] . The absence of Siglec-7 expression on natural killer cells and the increase in soluble serum levels suggest that these immune cells are dysfunctional in advanced liver disease [14] . Future studies may be able to better elicit whether modulation of the Siglec-7 pathway is a viable target of therapy. There are monoclonal antibodies that target Siglec-2 and Siglec-3 receptors and are treatments for hematologic malignancies [46] . Further investigation is required to clarify the effect of systemic inhibition of Siglec-7 receptors.
This study should be interpreted within the context of its limitations. This was a single-center study, which may limit generalizability of our results to other populations. To this point, our MELD score had relatively low c statistic for 90-day mortality compared to some other studies [47, 48] . External validation of our results in other cohorts is required, since they are exploratory in nature and thus should be considered hypothesis generating. We used the same commercial assay as Varchetta et al. for measuring serum Siglec-7; however, differences in laboratory processing may limit comparability of absolute values between our results. Because of sample size, we could not adjust for etiology of liver disease or fibrosis stage in our analysis. We were not powered to perform a subgroup analysis in subjects with Hepatitis C, though we show similar correlations between Siglec-7 and markers of liver fibrosis across a broader range of liver disease as previously shown in subjects with Hepatitis C. Given this study included only hospitalized patients, primarily with AKI, our findings are best applied to this population. Despite these limitations, we believe our results provide important validation and extension of prior work in Siglec-7 and make an important contribution to the literature.
Conclusion
Serum Siglec-7 levels were associated with increased mortality in a cohort of hospitalized patients with advanced liver disease and acute kidney injury. Addition of Siglec-7 to existing risk models such as MELD score increased discrimination to predict mortality at 90 days. There was no difference in Siglec-7 levels across subgroups of acute kidney injury. Further study of the association of serum Fig. 4 Change in serum Siglec-7 levels among subjects with 30-day follow-up measurements. Solid blue line represents mean Siglec-7 levels for each panel. Left subjects who received liver transplant between measurements. Right subjects who did not receive liver transplant
Siglec-7 and mortality should be performed in broader populations of cirrhosis to better delineate its role as a diagnostic marker and potential therapeutic target.
